Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.		FIRST NAMED APPLICANT			ATTY DOCKET NO.	
09/762916		OTTE	A	A 2799/64201		
03/102310				INTERNATIONAL APPLICATION NO.		
ROBERT D KATZ 1185 AVENUE OF THE AMERICAS				PCT/NL99/00518		
NEW YORK, NY 10036				1 A. FILING DATE	PRIORITY DATE	
				16 AUG 99	14 AUG 98	
NOTIFICATION CONTAINING	TO COMPLY WI G NUCLEOTIDE	TH REQUIREME SEQUENCE AND DISCLOSURES	OR AM	R PATENT AP	O APR 21 PLICATIONS QUENCE	

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the defici

deficienc	y noted below and avoid abandonment is set forth in the accompanying Notification.
The nucle with the reason(s)	eotide and/or amino acid sequence disclosure contained in this application does not comply requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following:
<u>*</u>	The state of the s
FOR QU	ANT MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as a amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). JESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE (703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help,
	(703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help, (703) 287-0200, for PatentIn software help.

Paulette Kidwell, Paralegal

Telephone: 703-305-3656